{"title":"[Changes in the echostructure of prostatic adenomas during drug therapy].","authors":"H P Szutrely","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Within the scope of a controlled double-blind study to demonstrate the effect of conservative therapy of benign prostatic hyperplasia with Harzol, ultrasonographic examination of the prostate adenoma was carried out on 23 patients before and after therapy with the trial preparation or placebo. Within a two-month treatment with Harzol, there was a significant change in the echo structure of the prostate adenoma, and this is interpreted as a reduction in the interstitial formation of oedema.</p>","PeriodicalId":79233,"journal":{"name":"Medizinische Klinik (Praxis-Ausg.)","volume":"77 18","pages":"42-6"},"PeriodicalIF":0.0,"publicationDate":"1982-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17247799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Physician's performance under the pressure for specialization and demand for complete care].","authors":"H Begemann","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":79233,"journal":{"name":"Medizinische Klinik (Praxis-Ausg.)","volume":"77 18","pages":"58-63"},"PeriodicalIF":0.0,"publicationDate":"1982-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18148259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[Therapy of obstructive respiratory tract diseases with pure theophylline retard].","authors":"P J Arens","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In an open study 19 patients with chronic obstructive lung disease were treated over nine days with Afonilum retard (1 capsule contains 250 mg pure theophylline in retard pellets form, the mite-form contains 125 mg pure theophylline in retard pellets form). Vital capacity (VC), forced expiratory volume (FEV1) and bronchial resistance (Rt) were measured before and on the third, sixth, and ninth day at eight o'clock and four hours later. Theophylline serum levels were measured by radioimmunoassay. In 14 patients 2 capsules (250 mg theophylline twice a day) were administered in twelve hours intervals. In this group lung function improved statistically significantly (p less than 0.01) for VC to 37%, FEV1 to 80% and Rt to 64% in comparison to the values before. Mean values of theophylline serum concentrations were 6.9 +/- 2.1 micrograms/ml at eight o'clock before the morning dose and 9.6 +/- 2.2 micrograms/ml four hours later on the ninth day. In five patients 375 mg theophylline were administered twice a day from third day on. In this group lung function improved for VC to 50%, FEV1 to 75% and Rt to 61% compared with the values before. Mean values of theophylline serum concentrations resulted in 10.8 +/- 3.6 micrograms/ml at eight o'clock before the morning dose and in 15.0 +/- 3.5 four hours later on the ninth day.</p>","PeriodicalId":79233,"journal":{"name":"Medizinische Klinik (Praxis-Ausg.)","volume":"77 18","pages":"48-53, 67"},"PeriodicalIF":0.0,"publicationDate":"1982-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"17805366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"[For which liver diseases is immunosuppressive therapy indicated?].","authors":"H Bannaski","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This paper reports on 464 cases of chronic hepatitis, of which 271 aggravated under the usual conservative treatment and thereafter were treated with an immunosuppressive agent. The results answer the question of \"when an immunosuppressive therapy is justified\". An improvement of liver diseases could be reached as follows: lupoid hepatitis 84%, chronic aggressive hepatitis with strong activity 78%, chronic aggressive hepatitis with low activity 53%, chronic persisting hepatitis 34%, mixed form of chronic aggressive hepatitis and primary biliary cirrhosis 34%, HBsAg-negative cirrhosis 57.9%, HBsAg-positive cirrhosis 60%, HBsAg-negative chronic aggressive hepatitis 66.7%, HbsAg-positive chronic aggressive hepatitis 76.2%.</p>","PeriodicalId":79233,"journal":{"name":"Medizinische Klinik (Praxis-Ausg.)","volume":"77 16-17","pages":"66-71, 74"},"PeriodicalIF":0.0,"publicationDate":"1982-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"18148365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}